GOSS vs. RIGL, CAPR, PRLD, SCPH, PRQR, ALIM, RPTX, GLSI, GALT, and CRVO
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Rigel Pharmaceuticals (RIGL), Capricor Therapeutics (CAPR), Prelude Therapeutics (PRLD), scPharmaceuticals (SCPH), ProQR Therapeutics (PRQR), Alimera Sciences (ALIM), Repare Therapeutics (RPTX), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 5.0% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Rigel Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -16.45%. Gossamer Bio's return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Rigel Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.
Rigel Pharmaceuticals received 307 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 65.16% of users gave Gossamer Bio an outperform vote.
In the previous week, Gossamer Bio had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Gossamer Bio and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.44 beat Gossamer Bio's score of 0.13 indicating that Gossamer Bio is being referred to more favorably in the news media.
Rigel Pharmaceuticals currently has a consensus price target of $5.81, suggesting a potential upside of 511.58%. Gossamer Bio has a consensus price target of $7.65, suggesting a potential upside of 1,002.31%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Rigel Pharmaceuticals.
Summary
Gossamer Bio beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
